0.26
price down icon9.28%   -0.03
after-market アフターアワーズ: .27 0.01 +3.85%
loading
前日終値:
$0.29
開ける:
$0.2898
24時間の取引高:
5.21M
Relative Volume:
0.72
時価総額:
$7.41M
収益:
$9.94M
当期純損益:
$-144.49M
株価収益率:
-0.0465
EPS:
-5.5956
ネットキャッシュフロー:
$-103.90M
1週間 パフォーマンス:
-4.36%
1か月 パフォーマンス:
-88.25%
6か月 パフォーマンス:
-95.34%
1年 パフォーマンス:
-90.93%
1日の値動き範囲:
Value
$0.26
$0.2898
1週間の範囲:
Value
$0.183
$0.3735
52週間の値動き範囲:
Value
$0.183
$8.17

Syros Pharmaceuticals Inc Stock (SYRS) Company Profile

Name
名前
Syros Pharmaceuticals Inc
Name
セクター
Healthcare (1195)
Name
電話
617-744-1340
Name
住所
35 CAMBRIDGE PARK DRIVE, CAMBRIDGE
Name
職員
68
Name
Twitter
@syrospharma
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
SYRS's Discussions on Twitter

SYRS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
SYRS 0.26 7.41M 9.94M -144.49M -103.90M -5.5956
VRTX 450.37 115.43B 10.63B -479.80M -1.35B 13.33
REGN 744.50 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 596.74 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.80 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 108.23 24.89B 3.30B -501.07M 1.03B 11.54

Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2020-11-04 アップグレード H.C. Wainwright Neutral → Buy
2020-09-22 開始されました Alliance Global Partners Buy
2020-01-17 ダウングレード Wedbush Outperform → Neutral
2019-03-08 再開されました JMP Securities Mkt Outperform
2019-02-14 再開されました Oppenheimer Outperform
2018-11-05 アップグレード ROTH Capital Neutral → Buy
2018-03-13 繰り返されました Wedbush Outperform
2017-10-31 再開されました Piper Jaffray Overweight
2017-10-23 開始されました ROTH Capital Neutral
2017-08-10 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
すべてを表示

Syros Pharmaceuticals Inc (SYRS) 最新ニュース

pulisher
06:40 AM

Syros pharmaceuticals chief medical officer sells shares for $2,382 By Investing.com - Investing.com Australia

06:40 AM
pulisher
06:40 AM

Syros Pharmaceuticals chief legal officer sells $10,320 in stock By Investing.com - Investing.com Australia

06:40 AM
pulisher
06:33 AM

Syros pharmaceuticals chief medical officer sells shares for $2,382 - Investing.com India

06:33 AM
pulisher
Nov 20, 2024

Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 - Investing.com

Nov 20, 2024
pulisher
Nov 20, 2024

Syros pharmaceuticals chief development officer sells shares for $7,949 By Investing.com - Investing.com UK

Nov 20, 2024
pulisher
Nov 20, 2024

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2024 Earnings Call Transcript - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Brookline Capital Downgrades Syros Pharmaceuticals (SYRS) - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Syros cut to neutral by H.C. Wainwright on failed drug study - MSN

Nov 19, 2024
pulisher
Nov 18, 2024

Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes - XM

Nov 18, 2024
pulisher
Nov 18, 2024

Syros Pharmaceuticals Faces Financial Struggles Amid Key Challenges - TipRanks

Nov 18, 2024
pulisher
Nov 17, 2024

What is HC Wainwright’s Forecast for SYRS Q1 Earnings? - Defense World

Nov 17, 2024
pulisher
Nov 15, 2024

Avidity Partners Management LP's Strategic Acquisition in Syros Pharmaceuticals Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Blue Owl Capital Holdings LP Increases Stake in Syros Pharmaceuticals Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Syros Pharmaceuticals (NASDAQ:SYRS) Earns Neutral Rating from HC Wainwright - Defense World

Nov 15, 2024
pulisher
Nov 14, 2024

Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright - Yahoo Finance

Nov 14, 2024
pulisher
Nov 14, 2024

JMP Securities cuts Syros Pharma stock rating following unsuccessful trial By Investing.com - Investing.com Australia

Nov 14, 2024
pulisher
Nov 13, 2024

Syros Pharmaceuticals' SWOT analysis: stock faces headwinds after trial setback - Investing.com Canada

Nov 13, 2024
pulisher
Nov 13, 2024

No RARA, Syros trouble: MDS phase III sinks tamibarotene - BioWorld Online

Nov 13, 2024
pulisher
Nov 13, 2024

Syros’s Hopes Dashed As Tamibarotene Flunks Phase III MDS Trial - Citeline News & Insights

Nov 13, 2024
pulisher
Nov 13, 2024

Syros Pharmaceuticals stock hits 52-week low at $0.4 By Investing.com - Investing.com Canada

Nov 13, 2024
pulisher
Nov 13, 2024

JMP Securities cuts Syros Pharma stock to Market Perform - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

U.S. Stock market: Syros Pharmaceuticals(−86.21%), GlucoTrack(−77.70%) and others among the most volatile stocks during mid day trading - Business Upturn

Nov 13, 2024
pulisher
Nov 13, 2024

Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default - Benzinga

Nov 13, 2024
pulisher
Nov 13, 2024

Syros Pharmaceuticals downgraded to Hold from Buy at TD Cowen - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Syros Pharmaceuticals stock hits 52-week low at $0.4 - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

Syros stock craters after lead cancer therapy flops in Phase III trial - Pharmaceutical Technology

Nov 13, 2024
pulisher
Nov 13, 2024

U.S. Stock market: Syros Pharmaceuticals surges by 680.00% while Spirit Airlines rises by 184.96% in early trading - Business Upturn

Nov 13, 2024
pulisher
Nov 13, 2024

Syros flunks phase 3 blood cancer trial, triggering loan default and share-price plunge - Fierce Biotech

Nov 13, 2024
pulisher
Nov 13, 2024

Syros Pharmaceuticals' (SYRS) Hold Rating Reiterated at Brookline Capital Management - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Analysts Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Target Price at $5.00 - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

JMP Securities Reiterates Market Perform Rating for Syros Pharmaceuticals (NASDAQ:SYRS) - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Syros Pharmaceuticals' (SYRS) "Hold" Rating Reaffirmed at TD Cowen - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Syros Pharmaceuticals Shares Plummet Premarket After Study Failure - MarketWatch

Nov 13, 2024
pulisher
Nov 13, 2024

Syros Crashes Over 90% on Late-Stage MDS Fail, Loan Default - BioSpace

Nov 13, 2024
pulisher
Nov 13, 2024

TD Cowen downgrades Syros Pharma stock to Hold on trial failure - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

Syros downgraded to Market Perform from Outperform at JMP Securities - TipRanks

Nov 13, 2024
pulisher
Nov 12, 2024

Syros stock dives 92% on failed Phase 3 study, possible loan default (update) - MSN

Nov 12, 2024
pulisher
Nov 12, 2024

Syros Pharmaceuticals trial fails to meet primary goal - Investing.com

Nov 12, 2024
pulisher
Nov 12, 2024

Syros Pharmaceuticals trial fails to meet primary goal By Investing.com - Investing.com UK

Nov 12, 2024
pulisher
Nov 12, 2024

Syros Pharma Stock Alert: Phase 3 Trial Fails, Loan Default Triggered | SYRS Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 04, 2024

Syros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Sell at StockNews.com - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

SYRS (Syros Pharmaceuticals) Total Inventories : $0.00 Mil (As of Sep. 2024) - GuruFocus.com

Nov 04, 2024
pulisher
Nov 04, 2024

Syros Pharmaceuticals, Inc. announced that it expects to receive $10 million in funding from Incyte Corporation - Marketscreener.com

Nov 04, 2024
pulisher
Nov 03, 2024

Incyte Corporation and yros Pharmaceuticals Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms - Marketscreener.com

Nov 03, 2024
pulisher
Nov 02, 2024

SYRSW (Syros Pharmaceuticals) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com

Nov 02, 2024
pulisher
Nov 02, 2024

Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023) - Yahoo Finance

Nov 02, 2024
pulisher
Nov 01, 2024

Syros Pharmaceuticals (NASDAQ:SYRS) Issues Quarterly Earnings Results - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Earnings call: Syros Pharmaceuticals outlines tamibarotene progress By Investing.com - Investing.com South Africa

Nov 01, 2024
pulisher
Nov 01, 2024

Earnings call: Syros Pharmaceuticals outlines tamibarotene progress - Investing.com India

Nov 01, 2024
pulisher
Nov 01, 2024

Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ... - Yahoo Finance

Nov 01, 2024

Syros Pharmaceuticals Inc (SYRS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Syros Pharmaceuticals Inc (SYRS) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Roth David
Chief Medical Officer
Nov 18 '24
Sale
0.20
12,099
2,382
0
Quirk Gerald E
Chief Legal & Compliance Offic
Nov 19 '24
Sale
0.22
46,657
10,321
0
Chee Conley
President & CEO
Nov 18 '24
Sale
0.20
134,797
26,932
0
Haas Jason
Chief Financial Officer
Nov 18 '24
Sale
0.21
137,803
28,980
0
$18.42
price down icon 1.07%
$70.68
price down icon 0.42%
$38.25
price up icon 3.56%
$367.36
price up icon 0.77%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
大文字化:     |  ボリューム (24 時間):